sorafenib has been researched along with belinostat in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (belinostat) | Trials (belinostat) | Recent Studies (post-2010) (belinostat) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 208 | 30 | 167 |
| 6,520 | 730 | 5,251 | 8 | 0 | 7 |
| Protein | Taxonomy | sorafenib (IC50) | belinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.1942 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.027 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.2147 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.1602 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 5.12 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.816 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2401 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.5966 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.2526 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.1946 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2147 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
| Dombi, E; Force, J; Giaccone, G; Rajan, A; Steinberg, SM | 1 |
| Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 trial(s) available for sorafenib and belinostat
| Article | Year |
|---|---|
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Retrospective Studies; Sorafenib; Sulfonamides; Survival Rate; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
3 other study(ies) available for sorafenib and belinostat
| Article | Year |
|---|---|
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |